Chronic Kidney Disease and Anemia

Deep Dive

From a western clinical perspective, anemia in chronic kidney disease arises from converging biological disruptions. The failing kidney loses it... From a western clinical perspective, anemia in chronic kidney disease arises from converging biological disruptions. The failing kidney loses its capacity to produce erythropoietin (EPO), which normally signals the marrow to generate red blood cells. Concurrently, CKD is a proinflammatory state. Inflammation elevates hepcidin, a master regulator of iron trafficking that blocks intestinal absorption and sequesters iron in macrophages. Even when ferritin is normal or high, transferrin saturation is often low—an indicator of functional iron deficiency. Uremia shortens red cell survival, and many patients experience ongoing iron loss via occult gastrointestinal bleeding, frequent phlebotomy, and hemodialysis circuit losses. These mechanisms explain why anemia prevalence increases as CKD advances and why dialysis patients often need sustained therapy. Diagnosis begins with confirming low hemoglobin and demonstrating hypoproliferation (low/normal reticulocytes), then assessing iron status with ferritin and transferrin saturation. B12 and folate deficiencies, thyroid disease, hemolysis, and bone marrow disorders are considered in the differential. KDIGO-aligned practice defines anemia in CKD similarly to WHO cutoffs—without stage-specific thresholds—but intensifies monitoring as CKD worsens (e.g., more frequent checks in stages 4–5 and dialysis). Treatment proceeds in layers. Iron repletion is foundational; oral iron can be useful in earlier stages, while intravenous iron is favored in hemodialysis due to poor absorption and high hepcidin. The PIVOTAL trial showed that proactive IV iron reduced hospitalizations and ESA doses without excess infections. When Hb remains low after iron optimization, erythropoiesis-stimulating agents (ESAs) are introduced cautiously. Large trials (CHOIR, CREATE, TREAT) demonstrated that aiming for near-normal Hb increases stroke and thrombotic events; therefore, partial correction with conservative targets and symptom-guided use is standard. Newer HIF–prolyl hydroxylase inhibitors offer an oral option that increases endogenous EPO signaling and may improve iron handling; approvals currently emphasize dialysis-dependent patients, with ongoing safety evaluation. Transfusions are reserved for specific situations and minimized in transplant candidates to avoid sensitization. Clinically, appropriately treated anemia improves fatigue, exercise tolerance, restless legs, and overall quality of life, and reduces transfusion exposure. While correcting anemia has not consistently improved survival or slowed CKD progression, under-treatment is linked with cardiovascular remodeling and hospitalization. Best care also addresses contributors—controlling inflammation, optimizing dialysis adequacy, managing CKD–mineral bone disorder, and identifying bleeding—while coordinating monitoring and shared decision-making.